Takayuki Yoshino, MD, PhD

IntroductionChemoradiotherapy (CRT) with surgery is standard for patients (pts) with locally advanced rectal cancer (LARC), and nivolumab (nivo) is active in microsatellite instability-h...

T. Sasaki ;

Y. Nishizawa ;

N. Nakamura ;

M. Wakabayashi ;

M. Kojima ;

Takayuki Yoshino , MD, PhD;

Y. Togashi ;

H. Bando ;

A. Sato ;

Y. Tsukada ;

H. Nishikawa ;

K. Inamori ;

M. Ito ;

S. Yuki ;

Y. Komatsu ;

S. Homma ;

M. Uemura ;

T. Kato ;

D. Kotani ;

S. Fukuoka ;

07/01/2019

Highlights of Posters at ESMO GI on colorectal cancer

Takayuki Yoshino , MD, PhD;

07/10/2018

Discussant: O-5, SO-23, O-6, SO-24, and LBA-3

Takayuki Yoshino , MD, PhD;

07/02/2021

Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

Background In the phase 3, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab versus chemotherapy provided superior progression-free survival (PFS) at second interim a...

J. Bendell ;

D. Le ;

Takayuki Yoshino , MD, PhD;

W. Zhong ;

T. Andre ;

D. Fogelman ;

K. Shiu ;

P. Marinello ;

T. Kim ;

L. Diaz ;

B. Jensen ;

L. Jensen ;

C. Punt ;

D. Smith ;

Rocio Garcia-Carbonero , MD, PhD;

J. Garcia Alcaide ;

P. Gibbs ;

C. De la Fouchardiere ;

F. Herrero Rivera ;

E. Elez ;

07/02/2021

Debate: 3 Months of CAPOX Should be The Standard of Care For All Stage 3 Colon Cancer Patients “No”

Takayuki Yoshino , MD, PhD;

07/03/2021

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;